Your browser doesn't support javascript.
loading
A Senolytic-Eluting Coronary Stent for the Prevention of In-Stent Restenosis.
Kim, Cheesue; Lee, Seul-Gee; Lim, Songhyun; Jung, Mungyo; Kwon, Sung Pil; Hong, Jihye; Kang, Mikyung; Sohn, Hee Su; Go, Seokhyeong; Moon, Sangjun; Lee, Seung-Jun; Kim, Jung-Sun; Kim, Byung-Soo.
Afiliação
  • Kim C; School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea.
  • Lee SG; Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Lim S; School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea.
  • Jung M; School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea.
  • Kwon SP; School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea.
  • Hong J; Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea.
  • Kang M; Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea.
  • Sohn HS; School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea.
  • Go S; Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea.
  • Moon S; School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea.
  • Lee SJ; Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Kim JS; Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Kim BS; Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
ACS Biomater Sci Eng ; 8(5): 1921-1929, 2022 05 09.
Article em En | MEDLINE | ID: mdl-35416659
ABSTRACT
The vast majority of drug-eluting stents (DES) elute either sirolimus or one of its analogues. While limus drugs stymie vascular smooth muscle cell (VSMC) proliferation to prevent in-stent restenosis, their antiproliferative nature is indiscriminate and limits healing of the endothelium in stented vessels, increasing the risk of late-stent thrombosis. Oxidative stress, which is associated with vascular injury from stent implantation, can induce VSMCs to undergo senescence, and senescent VSMCs can produce pro-inflammatory cytokines capable of inducing proliferation of neighboring nonsenescent VSMCs. We explored the potential of senolytic therapy, which involves the selective elimination of senescent cells, in the form of a senolytic-eluting stent (SES) for interventional cardiology. Oxidative stress was modeled in vitro by exposing VSMCs to H2O2, and H2O2-mediated senescence was evaluated by cytochemical staining of senescence-associated ß-galactosidase activity and qRT-PCR. Quiescent VSMCs were then treated with the conditioned medium (CM) of H2O2-treated VSMCs. Proliferative effects of CM were analyzed by staining for proliferating cell nuclear antigen. Senolytic effects of the first-generation senolytic ABT263 were observed in vitro, and the effects of ABT263 on endothelial cells were also investigated through an in vitro re-endothelialization assay. SESs were prepared by dip coating. Iliofemoral arteries of hypercholesteremic rabbits were implanted with SES, everolimus-eluting stents (EESs), or bare-metal stents (BMSs), and the area of stenosis was measured 4 weeks post-implantation using optical coherence tomography. We found that a portion of H2O2-treated VSMCs underwent senescence, and that CM of H2O2-treated senescent VSMCs triggered the proliferation of quiescent VSMCs. ABT263 reverted H2O2-mediated senescence and the proliferative capacity of senescent VSMC CM. Unlike everolimus, ABT263 did not affect endothelial cell migration and/or proliferation. SES, but not EES, significantly reduced stenosis area in vivo compared with bare-metal stents (BMSs). This study shows the potential of SES as an alternative to current forms of DES.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reestenose Coronária / Stents Farmacológicos Limite: Animals Idioma: En Revista: ACS Biomater Sci Eng Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reestenose Coronária / Stents Farmacológicos Limite: Animals Idioma: En Revista: ACS Biomater Sci Eng Ano de publicação: 2022 Tipo de documento: Article
...